How Stem Cell Aging Works and What Scientists Are Doing to Reverse It
A comprehensive 2025 review maps the mechanisms behind MSC senescence and surveys emerging rejuvenation strategies for cell-based therapies.
Summary
Mesenchymal stem cells (MSCs) are among the most promising tools in regenerative medicine, but they age—both in elderly donors and during lab expansion. This 2025 review catalogs how senescent MSCs change morphologically, biochemically, and functionally, including flattened cell shapes, elevated SA-β-gal activity, SASP secretion, reduced migration, and skewed differentiation. Key senescence pathways include p53/p21, p16/Rb, mTOR, and NF-κB. The review also surveys rejuvenation strategies such as genetic reprogramming, pharmacological senolytics, hypoxic preconditioning, and extracellular vesicle-based approaches—all aimed at producing youthful, high-quality MSCs for clinical use.
Detailed Summary
As the global population ages rapidly—with over 200 million people aged 65+ in China alone and the WHO projecting one in six people worldwide will be over 65 by 2050—the demand for effective regenerative therapies has intensified. Mesenchymal stromal/stem cells (MSCs) represent one of the most clinically evaluated cell therapies, with nearly 1,500 registered trials, but their therapeutic potential is critically undermined by senescence, whether arising from donor age or prolonged in vitro expansion.
This 2025 comprehensive review from Chinese research institutions systematically characterizes MSC senescence across multiple dimensions. Senescent MSCs display distinct morphological hallmarks—enlarged, flattened 'fried egg' morphology—alongside downregulation of canonical surface markers (CD73, CD90, CD105) and upregulation of senescence indicators like CD26 and CD264. Intracellularly, SA-β-gal activity rises, p16, p21, and p53 expression increases, and cell cycle arrest becomes permanent in G0. The authors also highlight emerging biomarkers including α-l-fucosidase (α-fuc), extrachromosomal circular DNA (eccDNA), and intracellular ATP levels as complementary senescence indicators.
A central feature of senescent MSCs is the senescence-associated secretory phenotype (SASP), characterized by secretion of IL-6, IL-8/CXCL8, MCP-1/CCL2, and insulin-like growth factor binding proteins (IGFBPs). These factors propagate senescence to neighboring cells via paracrine signaling, amplify bone marrow inflammation, and contribute to age-related osteoporosis. Key signaling pathways driving these changes include p38MAPK/NF-κB, p53/p21/Rb, p16/Rb, PI3K/AKT/mTOR, and ROS-prostaglandin cascades. Functionally, senescent MSCs show reduced proliferation, impaired migration (with decreased CXCR4, CXCR7, and MMP expression), diminished antioxidant capacity (lower SOD1-3, GPX, catalase), and a biased differentiation shift favoring adipogenesis over osteogenesis.
The review's most translational section surveys rejuvenation interventions. These include partial epigenetic reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), pharmacological approaches with senolytics (e.g., dasatinib, quercetin) and senomorphics (rapamycin targeting mTOR), hypoxic preconditioning to reduce ROS and enhance stemness, and extracellular vesicle or exosome-based strategies that transfer rejuvenating signals without full cellular reprogramming. Genetic engineering approaches and optimized culture conditions (3D spheroid culture, antioxidant supplementation) are also discussed as practical manufacturing improvements.
The review concludes that overcoming MSC senescence is essential for realizing the full promise of personalized and universal MSC-based therapies. While multiple promising strategies exist, standardization of senescence detection methods and validation in large-scale clinical trials remain critical next steps before these rejuvenation approaches can be broadly implemented.
Key Findings
- Senescent MSCs show enlarged flat morphology, elevated SA-β-gal, and upregulated p16/p21/p53, signaling permanent cell cycle arrest.
- SASP components like IL-6, IL-8, and IGFBPs spread senescence paracrine signals, amplifying inflammation and age-related bone loss.
- CD26 and CD264 emerge as novel surface senescence markers; CD26 inhibition reversed senescence gene expression and improved lung repair in mice.
- Epigenetic reprogramming, senolytics, hypoxic preconditioning, and exosome-based strategies show promise for restoring MSC youthfulness.
- Intracellular ATP, α-l-fucosidase activity, and eccDNA profiles offer new complementary biomarkers beyond traditional SA-β-gal detection.
Methodology
This is a narrative review synthesizing published experimental and clinical literature on MSC senescence mechanisms and rejuvenation strategies. The authors drew from in vitro studies using bone marrow, adipose, and umbilical cord-derived MSCs across multiple passage numbers, as well as donor-age comparison studies and animal models. No original experimental data were generated by the review authors.
Study Limitations
As a narrative review, the paper does not perform meta-analysis or systematic evidence grading, limiting the strength of comparative conclusions across studies. Many rejuvenation strategies discussed remain at preclinical or early-phase stages, and long-term safety data—particularly for reprogramming approaches—are lacking. Heterogeneity in MSC tissue sources, donor demographics, and passage definitions across cited studies makes direct comparisons difficult.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: